Clinical efficacy and safety of immunotherapy after concurrent chemoradiotherapy in advanced esophageal cancer

Purpose To investigate the efficacy and feasibility of PD-1 antibody combined with concurrent chemoradiotherapy on patients with esophageal cancer. Methods From July 2020 to October 2023,15 patients with esophageal cancer in Zhejiang Quhua Hospital were treated with PD-1 monoclonal antibody after concurrent chemoradiotherapy. Recording the incidence of adverse reactions, Kaplan Meier was used to evaluate the median survival and overall survival of patients. Results All 15 patients were enrolled, with a median follow-up of 23.0 months(ranging from 6.0ཞ37.5 months). 1-year and 2-year OS were 93.3% and 46.7%, respectively. No treatment-related deaths were reported. Conclusion A certain survival benefit of concurrent chemoradiotherapy combined with PD-1 antibody is affirmed for patients with esophageal cancer, which is worthy of further clinical exploration.